Pfizer’s Eliquis Q1 Sales Jump 16% to $4.14 Billion Pre-Earnings
PFE•Pfizer’s co-marketed blood thinner Eliquis delivered $4.14 billion in Q1 sales, a 16% year-on-year increase driven by strong new prescription share above 75%. Investors are awaiting its March-quarter results, with Wall Street analysts refining estimates for revenue and key performance metrics.
1. Eliquis Q1 Sales Overview
In the first quarter, Eliquis generated $4.14 billion in global sales, representing a 16% increase from the prior year as new prescription share exceeded 75%.
2. Pfizer Partnership Role
Pfizer co-markets Eliquis with Bristol Myers Squibb, securing a significant position in the anticoagulant market and contributing to its joint revenues.
3. Q1 Earnings Preview
Pfizer is preparing to release its March-quarter earnings, with analysts updating forecasts for revenue, earnings per share and growth in vaccine and oncology segments.
4. Analyst Expectations
Investors are focused on top-and-bottom-line estimates as well as key segment metrics to assess whether Pfizer can sustain momentum in its core businesses.
